Heat Biologics - 3 Krebsmittel in der Pipeline!
Seite 148 von 176 Neuester Beitrag: 27.04.24 15:03 | ||||
Eröffnet am: | 17.09.13 23:22 | von: Balu4u | Anzahl Beiträge: | 5.38 |
Neuester Beitrag: | 27.04.24 15:03 | von: Highländer49 | Leser gesamt: | 1.169.705 |
Forum: | Hot-Stocks | Leser heute: | 119 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 146 | 147 | | 149 | 150 | ... 176 > |
On December 19, 2019, Heat Biologics, Inc. (the "Company") received a written notice (the "Notice") from the Listing Qualifications department of The Nasdaq Stock Market ("NASDAQ") that the Company had been granted an additional 180 calendar days, or until June 15, 2020, to regain compliance with the minimum $1.00 bid price per share requirement of the Listing Rules of Nasdaq (the "Minimum Bid Price Requirement") as required by NASDAQ Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.
https://m.marketscreener.com/...ued-Listing-Rule-or-Standar-29755761/
https://old.nasdaq.com/symbol/htbx/institutional-holdings/activity
Artikel: Heat Biologics: COVID-19 Vaccine Testing Imminent, Many Upcoming Catalysts And Substantial Upside Potential
Heat Biologics announced it would commence preclinical testing for its COVID-19 vaccine this quarter and it is finalizing manufacturing plans. The company also stated that it is applying for grants to support clinical development of this program and are advancing collaboration discussions.
Jeff Wolf, Chief Executive Officer of Heat Biologics, commented during the company’s First Quarter 2020 Business Update:
"We continue to make progress advancing our unique COVID-19 vaccine utilizing our robust gp-96 vaccine platform in collaboration with researchers at University of Miami. We plan to commence preclinical testing for the COVID-19 vaccine this quarter and are finalizing our manufacturing plans, which we believe will help shorten the clinical timeline. Additionally, we are applying for grants to support clinical development of this program and are advancing collaboration discussions.“
Therefore, the company could release a set of good news within the next six weeks, regarding the commencement of preclinical testing for the COVID-19 vaccine, grants to support clinical development and potential collaborations.
Even though these catalysts may be enough to warrant a substantial increase in the company’s stock price, there are more catalysts in the near future.
The company announced that it would present additional HS-110 data in combination with Opdivo® at the upcoming ASCO Conference on May 29 and that it plans to initiate an end of Phase 2 Type B meeting with the FDA.
Wird auf jeden Fall im restlichen Mai hier sehr spannend werden...
Gruß vom
Advamillionär
Nu' muss ich drei Tage lang hungrig beim Bett geh'n :-((
Der Chart ähnelt dem von Trevena, wäre zu schön, wenn es hier ähnlich weitergehen würde. Für morgen bin ich absolut optimistisch, mit bißchen Glück knacken wir morgen sogar schon die magische 1 USD-Marke.
Nachdem zuletzt hier kaum noch Bewegung drin war, bin ich nun doch froh, geduldig und drin geblieben zu sein. Schaun mer mal wie es weitergeht...
Gruß vom
Advamillionär
https://finance.yahoo.com/amphtml/news/...l?__twitter_impression=true
ASCO20 Virtual Scientific Program Schedule:
Wednesday, May 13: The majority of abstracts accepted for publication at the virtual meeting and for online publication will be released on schedule at 5:00 pm ET.
Friday, May 29: Oral, poster, and poster discussion sessions, as well as track-based Clinical Science Symposia, will be available on demand. Registrants will have exclusive access to hundreds of video and slide presentations, as well as discussant commentary for 180 days.
Saturday, May 30 (All sessions to be hosted in ET)
9:30 am: Opening Session with keynote address from ASCO President Howard A. “Skip” Burris III, MD and Guest Speaker Address by David Fajgenbaum, MD
10:30 am: Highlights Sessions: Breast Cancer; Head and Neck Cancer
11:00 am: Highlights Sessions: Gastrointestinal Cancers; Central Nervous System Tumors
https://meetings.asco.org/am/virtual-format
https://investorshub.advfn.com/HEAT-BIOLOGICS-INC-HTBX-29469/
Wie immer gilt dass es keine Kaufempfehlung und keiner fährt Kaufempfehlung jeder muss selbst entscheiden auf den Knopf drücken